Recombinant Mouse Semaphorin 4A mFc Chimera Protein, CF

When Recombinant Mouse Semaphorin 4A mFc Chimera Protein (Catalog #11096-S4) is immobilized at 2.0 µg/mL (100 µL/well), the concentration of Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein (2078-T4) that produces 50% of the optimal binding response is 0.100-0.600 μg/mL

2 μg/lane of Recombinant Mouse Semaphorin 4A mFc Chimera Protein (Catalog # 11096-S4) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 90-110 kDa and 180-220 kDa, respectively.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse Semaphorin 4A mFc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Mouse Semaphorin 4A mFc Chimera (Catalog # 11096-S4) is immobilized at 2.0 µg/mL (100 µL/well), the concentration of Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein (Catalog # 2078-T4) that produces 50% of the optimal binding response is 0.100-0.600 μg/mL
• Source: Mouse myeloma cell line, NS0-derived mouse Semaphorin 4A protein
  

  Mouse Sema 4A (Thr33-Phe683) Accession # Q62178.2	IEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: Q62178.2
• N-terminal Sequence: Thr33
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 99 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 90-110 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse Semaphorin 4A mFc Chimera Protein, CF

• CORD10
• RP35
• Sema B
• sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and shortcytoplasmic domain, (semaphorin) 4A
• SEMA4A
• SEMAB
• Semaphorin 4A
• semaphorin-4A
• semaphorin-B
• SEMB
• SEMBFLJ12287

Background

Semaphorin 4A (Sema4A), also known as Semaphorin-B (SEMB), is a Class 4 transmembrane Semaphorin with activity in the immune and nervous systems (1). Semaphorins are a large family of secreted and membrane-bound glycoproteins, divided into eight subclasses, that were initially implicated in axon guidance and neural development. Mature Sema4a consists of an extracellular domain (ECD) containing sema, PSI and C2-type immunoglobulin domains, a transmembrane domain, and a cytoplasmic domain with two Ser/Thr phosphorylation sites. The ECD of mature mouse Sema4A shares 87% and 94% amino acid sequence identity with human and rat Sema4a, respectively. Several splice variants have been reported with varying truncations in the ECD, transmembrane or cytoplasmic domains (3). Sema4A was first described as a molecule that enhances T cell activation and interacts with TIM-2 (T cell immunoglobulin and mucin domain-2 (4). Sema4a has also been shown to bind to the receptor ILT-4 on activated CD4+ cells (5). Mice with targeted disruption of Sema4A show defects in dendritic cell-mediated T cell priming and Th1 responses (6). Roles for Sema4A have also been identified in the brain, the endothelium and the eye. It mediates hippocampal neuron growth cone collapse in vitro through interaction of the sema domain with plexin-B1 (7). Interaction of Sema4A with endothelial cell plexin-D1 causes opposition to the angiogenic, proliferative, chemotactic and integrin-mediated adhesive actions of VEGF (8). The retina of Sema4A-/- mice shows severe degeneration, and mutations of Sema4A are associated with retinitis pigmentosa and cone rod dystrophy in humans (9, 10).

1. Kumanogoh, A. et al. (2003) J. Cell Sci. 116:3463.
2. Swissprot Accession # Q9H3S1.
3. Entrez Accession # CAI15528, CAI15529, CAI15531, CAI15532, CAI15533 and EAW52993.
4. Kumanogoh, A. et al. (2002) Nature 419:629.
5. Lu, N. et al. (2018) Nature Commun. 9:742.
6. Kumanogoh, A. et al. (2005) Immunity 22:305.
7. Yukawa, K. et al. (2005) Int. J. Mol. Med. 16:115.
8. Toyofuku, T. et al. (2007) EMBO J. 26:1373.
9. Rice, D.S. et al. (2004) Invest. Ophthalmol. Vis. Sci. 45:2767.
10. Abid, A. et al. (2007) J. Med. Genet. 43:378.

Bioinformatics

• Uniprot:
  • Q62178.2()